Group 1: Financial Performance - In the first half of 2025, the company achieved revenue of 2.417 billion yuan, a decrease of 14.55% compared to the same period last year [2] - The non-recurring net profit loss was 49 million yuan, significantly narrowing compared to the previous year [2] - The overall gross margin improved from approximately 26% in 2024 to nearly 30% in the first half of 2025, indicating enhanced operational and contract quality [4] Group 2: Business Strategy and Operations - The company is focusing on improving operational quality, with efforts including increased international business expansion, which saw nearly 40% growth in overseas revenue in the first half of 2025 [2] - Domestic order quality is improving, with new order gross margins gradually returning to normal levels despite intense competition in the domestic market [2] - The company is actively pursuing cost reduction and efficiency improvements across management, R&D, procurement, and manufacturing [2] Group 3: International Business Development - The company’s international business has seen significant changes, with major pharmaceutical companies beginning supplier audits, leading to breakthroughs in cooperation [3] - In the first half of 2025, the company experienced strong growth in the Middle East and Southeast Asia, with hopes of increasing the proportion of international business in the coming years [2][3] - Romaco Group, a subsidiary, is performing well with steady improvements, and currently has no plans for further overseas capacity expansion [3] Group 4: Market Conditions and Competition - The domestic market remains competitive, with price sensitivity; however, the price competition has improved compared to last year, suggesting a bottoming out of pricing pressures [3] - The company plans to selectively abandon low-margin orders to enhance operational quality while maintaining scale [3]

Core Insights - The company reported a revenue of RMB 146.86 billion for the six months ending June 30, 2025, representing a year-on-year increase of 9.26% [1] - The gross profit reached RMB 19.06 billion, up 4.08% year-on-year, while the profit attributable to shareholders was RMB 5.738 billion, reflecting a 19.37% increase [1] - The basic earnings per share were RMB 1.16, with a proposed interim cash dividend of RMB 4.6 per 10 shares [1] Revenue Breakdown - The express logistics business generated revenue of RMB 109.3 billion, a year-on-year increase of 10.4%, with accelerated growth in the second quarter compared to the first [2] - Supply chain and international business revenue was RMB 34.2 billion, up 9.7% year-on-year, despite challenges from international trade policies [2] - Other non-logistics business revenue amounted to RMB 3.3 billion, primarily from the procurement of raw materials or equipment within the end-to-end supply chain services [2] Profitability and Cost Management - The company achieved a gross profit of RMB 19.1 billion in the first half of 2025, a 4.1% year-on-year increase, with a gross margin of 13.0%, down 0.6 percentage points [3] - The company adopted flexible business strategies to expand its scale and improve asset efficiency, which helped mitigate the impact of increased competition and uncertain international trade conditions [3] - Management and R&D expense ratios decreased by 0.5 and 0.2 percentage points respectively, while the sales expense ratio slightly increased by 0.1 percentage points due to accelerated sales team development [3]

Group 1 - The core viewpoint is that Jiangsu Shentong is facing challenges due to a decline in the steel metallurgy industry's prosperity, leading to reduced market demand for its valve products and increased competition [2] - The company is enhancing product research and development, as well as process innovation, to address these challenges and implement cost reduction and efficiency improvement measures [2] - Jiangsu Shentong is increasing marketing efforts for its "Valve Butler" service to enhance brand influence and market share [2] Group 2 - The capital expenditure pace in the global and domestic chemical and refining industries is slowing down, resulting in intensified competition for the company's energy and chemical products [2] - The company plans to continue investing in research and development in the energy and chemical sector and innovate marketing models to gradually increase its market share in the energy and petrochemical valve products [2]

Investment Rating - The report maintains a "Recommended" rating for the company [6] Core Views - The company achieved significant profit growth in Q2 2025, with a net profit of 1.55 billion yuan, a year-on-year increase of 122.87% despite a revenue decrease of 26.66% [1][2] - The company is focusing on cost reduction and efficiency improvement, which is expected to continue driving performance recovery [4] - The commercial vehicle market is showing signs of recovery, supporting demand for the company's products [4] Summary by Sections Financial Performance - In H1 2025, the company reported revenue of 8.694 billion yuan, a year-on-year decrease of 21.71%, while net profit reached 405 million yuan, an increase of 148.75% [1] - Q2 2025 saw revenue of 4.349 billion yuan, a slight increase of 0.07% quarter-on-quarter but a decrease of 26.66% year-on-year [1] - The company's net profit for Q2 2025 was 155 million yuan, down 38.18% quarter-on-quarter but up 122.87% year-on-year [1] Production and Sales - Q2 2025 production and sales were impacted by scheduled maintenance, with steel sales at 1.0209 million tons, down 10.63% year-on-year and 0.75% quarter-on-quarter [2] - The gross profit per ton of steel remained relatively high at 348 yuan, despite a decrease of 39 yuan quarter-on-quarter and an increase of 38 yuan year-on-year [2] Strategic Initiatives - The company is implementing refined management practices to maintain cost competitiveness, optimizing raw material procurement and production costs [3] - The company is expanding its product line in the automotive spring steel market, enhancing its position in the commercial vehicle sector [3] Market Outlook - The commercial vehicle market in China showed growth in H1 2025, with production and sales increasing by 4.7% and 2.6% year-on-year, respectively [4] - The demand for automotive leaf springs and flat springs is expected to support the company's performance [4] Earnings Forecast - Projected net profits for the company from 2025 to 2027 are 791 million yuan, 916 million yuan, and 984 million yuan, respectively, with corresponding PE ratios of 16x, 14x, and 13x [5]

Core Viewpoint - The company, Shuoshi Biological, announced voluntary salary reductions for its executives in response to challenging market conditions and declining performance, reflecting a commitment to long-term development and cost efficiency [1][3]. Executive Salary Reduction - Eight executives, including the honorary chairman and the chairman, will see salary cuts ranging from 5% to 50%, with the honorary chairman's salary reduced by 50% and the chairman's by 50% as well [1]. - Five of the seven executives who voluntarily reduced their salaries had annual salaries exceeding 1 million yuan in 2024, with specific figures including 2.0643 million yuan for the honorary chairman and 2.4399 million yuan for the chairman [1]. Financial Performance - The company's revenue showed significant growth from 17.40 billion yuan in 2020 to 55.35 billion yuan in 2022, but it faced a drastic decline in 2023 with revenue dropping to 4.03 billion yuan and a net loss of 374 million yuan [3]. - For the first half of 2025, the company reported a revenue of 176 million yuan, a year-on-year decrease of 1.05%, and a net profit of 39.926 million yuan, down 86.35% compared to the previous year [3]. Dividend Distribution - Despite the decline in performance and executive salary cuts, the company approved a cash dividend of 3.4 yuan per 10 shares, totaling 285 million yuan, indicating a desire to reward investors while maintaining a healthy cash flow [4]. - The company emphasized its commitment to balancing dividends with future research and development investments, stating that technology innovation remains a core driver [4]. Market Position - As of August 28, the company's stock price was 63.92 yuan per share, with a total market capitalization of 5.316 billion yuan, reflecting its current market standing [5].

Core Viewpoint - The management team of Shuoshi Biology (688399) voluntarily proposed salary reductions ranging from 5% to 50% to support the company's operational cost optimization and enhance management efficiency in response to challenging global economic conditions and industry environment [2][5]. Salary Reduction Details - The honorary chairman, Fang Yongsheng, and the chairman and general manager, Wang Guoqiang, will have their annual salaries reduced by 50% starting from August 15, 2025 [3][4]. - Other executives, including Liu Zhonghua (director and deputy general manager), Hu Yuanyuan (director, deputy general manager, and board secretary), and Zhou Guohui (deputy general manager), will see a 40% reduction [3][4]. - The financial director, Meng Yuanyuan, and employee supervisors, Jia Zhaoqiang and Gu Lina, will have their salaries reduced by 10% and 5%, respectively [3][4]. Company Performance - Shuoshi Biology reported a significant decline in performance, with a net profit loss of 374 million yuan in 2023, a 120.45% year-on-year decrease [5][6]. - The company's revenue for the first half of 2025 was 176 million yuan, a decrease of 1.05% compared to the previous year, with a net profit of 3.99 million yuan, down 86.35% year-on-year [6][7]. - The company has faced continuous pressure on its operations, with two consecutive years of net profit losses [5][6]. Market Context - The decline in performance is attributed to the pressure on product prices due to the nationwide implementation of centralized procurement in the in vitro diagnostic industry, along with changes in tax rates and reduced government subsidies [7][8]. - As of August 27, 2023, Shuoshi Biology's stock price was 63.08 yuan per share, with a total market capitalization of 5.3 billion yuan [9].

Core Viewpoint - Jiangsu Shuoshi Biotechnology Co., Ltd. announced voluntary salary reductions for its executives and board members to support operational cost optimization and enhance competitiveness amid challenging global economic conditions [1][3]. Salary Reduction Details - The honorary chairman, Fang Yongsheng, and the chairman and general manager, Wang Guoqiang, will have their annual salaries reduced by 50% starting from August 15, 2025 [2][3]. - Other executives, including Liu Zhonghua and Hu Tongyuan, will see a 40% reduction, while the financial director, Meng Yuanyuan, and employee supervisors will have reductions of 10% and 5%, respectively [2][3]. Company Performance Context - Shuoshi Biotechnology experienced significant revenue growth during the pandemic, with revenues soaring from 289 million yuan in 2019 to 5.535 billion yuan in 2022, but faced a dramatic decline in 2023 with revenues dropping to 403 million yuan, a 92.72% decrease year-over-year [4][5]. - The company reported a net loss of 374 million yuan in 2023, marking a 120.45% decline compared to the previous year [4][5]. Future Strategies - The company aims to continue optimizing operations and enhancing market competitiveness through cost reduction and efficiency improvement measures [3][4].

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company's performance exceeded expectations despite a decline in oil prices, driven by cost reduction and efficiency improvements [6] - Oil and gas production reached a new high, effectively mitigating the impact of falling oil prices [6] - The company maintains a strong cash flow and a substantial mid-term dividend payout ratio [6] Financial Data and Earnings Forecast - Total revenue for 2025 is estimated at 444,457 million, with a year-on-year growth rate of 5.7% [5] - Net profit attributable to shareholders is projected to be 139,927 million for 2025, reflecting a slight increase of 1.4% year-on-year [5] - Earnings per share for 2025 is expected to be 2.94 [5] - The company achieved a gross margin of 51.6% for 2025, with a return on equity (ROE) of 17.0% [5] - The estimated price-to-earnings (PE) ratios for 2025, 2026, and 2027 are 9X, 8X, and 8X respectively [6]

Investment Rating - The report maintains an "Accumulate" rating for the company [9] Core Views - The company has shown significant cost reduction and efficiency improvement, indicating the emergence of an operational turning point [3] - In H1 2025, the company achieved revenue of 922 million RMB, a year-on-year increase of 25.86%, while the net profit attributable to shareholders was 11.93 million RMB, a year-on-year decrease of 52.23% [3][9] - The second quarter saw a revenue of 520 million RMB, with a year-on-year increase of 83.15% and a quarter-on-quarter increase of 29.36% [3] Summary by Sections Financial Performance - The comprehensive gross margin for H1 2025 was 15.31%, a decrease of 8.01 percentage points year-on-year; however, the gross margin for Q2 was 24.54%, an increase of 4.27 percentage points year-on-year and 21.16 percentage points quarter-on-quarter [4] - The company has improved its management expenses control, with a period expense ratio of 16.28%, down 8.22 percentage points year-on-year [5] - Operating cash flow for H1 2025 was 75 million RMB, a year-on-year increase of 198.64% [5] Market Position and Product Performance - The company has successfully tapped into emerging markets, with significant sales growth in new energy products, including a 200% increase in wind energy products [4] - The average price of acrylonitrile in the first eight months of 2025 was 8,949 RMB/ton, a decrease of 2.6% compared to the entire year of 2024, indicating a stabilization in carbon fiber prices [6] Profit Forecast and Valuation - The report has adjusted the profit forecast for 2025-2027, with net profit estimates of 148 million RMB, 273 million RMB, and 422 million RMB respectively, reflecting a compound annual growth rate (CAGR) of 68.88% [7] - The target price has been raised to 31.80 RMB, based on a price-to-book (PB) ratio of 6 times for 2025 [7][10]

Group 1: Impact of Tariff Policies - The U.S. market accounts for approximately 40% of the company's sales revenue, and the increase in import tariffs will raise costs for customers selling to the U.S. market [2] - Customers typically bear the tariff costs, which are ultimately passed on to consumers; some customers are currently discussing cost issues related to tariffs with the company [2] Group 2: Customer Orders and Market Dynamics - In the first half of the year, customer orders showed divergence; while some existing customers experienced a decline in orders, new customer orders increased significantly year-on-year [2] - The uncertainty in U.S. trade policies and macroeconomic conditions affects customer sales forecasts and order placements [2][3] Group 3: Gross Margin and Production Efficiency - The overall gross margin has declined compared to the same period last year due to new factories being in the ramp-up phase; it typically takes 10-12 months for a new factory to reach breakeven [4] - One new factory achieved profitability in Q2, and its gross margin improved compared to Q1; operational efficiency is expected to gradually increase as new employees become more skilled [4] Group 4: Production Capacity and Utilization - The company has flexible production capacity, which is adjusted based on annual order conditions; target capacity is set according to the current stage of the factory and order types [5] - New factories have their target capacity set based on the number of production lines and employee proficiency rather than theoretical maximum output [5] Group 5: Client Diversification Strategy - The company has a strong reputation as a quality manufacturer, attracting clients; it has implemented a moderate diversification strategy, with significant revenue growth from new clients in the first half of the year [6] - Future disclosures will be made regarding new clients contributing to revenue [6]